索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]苏冠华,孙雨霏.心力衰竭的免疫调节治疗[J].国际心血管病杂志,2015,06:384-387.
点击复制

心力衰竭的免疫调节治疗(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2015年06期
页码:
384-387
栏目:
综述
出版日期:
2015-11-25

文章信息/Info

Title:
-
作者:
苏冠华; 孙雨霏
430022 武汉,华中科技大学同济医学院附属协和医院心内科(苏冠华); 430070 武汉,华中科技大学同济医学院附属武汉普爱医院心内科(孙雨霏)
Author(s):
-
关键词:
心力衰竭; 炎症; 免疫调节; 免疫吸附
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2015.06.005
文献标识码:
-
摘要:
近年来,炎症免疫系统功能失衡在心力衰竭病程中的作用越来越受到关注。以炎症介质和免疫调节为靶向的治疗主要包括:(1)使用生物制剂靶向拮抗促炎细胞因子,如应用可溶性TNF-α受体依那西普、抗TNF-α单克隆抗体英夫利昔单抗;(2)免疫调节策略改变炎症介质水平,如抗氧化疗法、静脉注射免疫球蛋白或干扰素、免疫调节治疗、免疫吸附疗法、他汀药物治疗等。
Abstract:
-

参考文献/References

[1] 王 君, 郑 兴. 心力衰竭新药的临床研究[J]. 国际心血管病杂志, 2014, 41(2): 72-74.
[2] Oikonomou E, Tousoulis D, Siasos G, et al. The role of inflammation in heart failure: new therapeutic approaches [J]. Hellenic J Cardiol, 2011, 52(1): 30-40.
[3] Cialdella P, Pedicino D, Gustapane M, et al. Inflammatory markers in heart failure: hype or hope? [J]. J Cardiovasc Med(Hagerstown), 2013, 14(5): 342-350.
[4] Yndestad A, Damas JK, Oie E, et al. Role of inflammation in the progression of heart failure [J]. Curr Cardiol Rep, 2007,9(3): 236-241.
[5] Gullestad L, Kjekshus J, Damas JK, et al. Agents targeting inflammation in heart failure [J]. Expert Opin Investig Drugs, 2005, 14(5): 557-566.
[6] Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology [J].Eur J Heart Fail,2009, 11(2): 119-129.
[7] Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation(RENEWAL)[J]. Circulation, 2004, 109(13): 1594-1602.
[8] Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure(ATTACH)trial [J]. Circulation,2003, 107(25): 3133-3140.
[9] 程 翔, 廖玉华, 李 彬, 等. 早期美托洛尔治疗对急性心肌梗死大鼠心肌炎症因子表达和心功能的影响[J]. 中华心血管病杂志,2005, 33(5): 448-452.
[10] McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy [J]. Circulation, 1997, 95(11): 2476-2478.
[11] Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure [J]. Circulation, 2001, 103(2): 220-225.
[12] Dennert R, Velthuis S, Schalla S, et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load [J]. Antivir Ther, 2010,15(2): 193-201.
[13] Gullestad L, Orn S, Dickstein K, et al. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction [J]. Int J Cardiol, 2013, 168(1): 212-218.
[14] Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction [J]. Circulation, 2003, 107(22): 2793-2798.
[15] Keren A. Invited for debate: is virus persistence a determinant for disease progression? [J] Ernst Schering Res Found Workshop, 2006,(55): 55-61.
[16] Levick SP, Goldspink PH. Could interferon-gamma be a therapeutic target for treating heart failure? [J] Heart Fail Rev, 2014, 19(2): 227-236.
[17] Sporter RJ, Kim JH, Frishman WH. Device-based nonspecific immunomodulation therapy(Celacade), and its potential role in the treatment of chronic heart failure [J]. Cardiol Rev, 2008, 16(6): 280-287.
[18] Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure(ACCLAIM trial): a placebo-controlled randomised trial [J]. Lancet, 2008, 371(9608): 228-236.
[19] Kaya Z, Leib C, Katus HA.Autoantibodies in heart failure and cardiac dysfunction [J].Circ Res, 2012, 110(1): 145-158.
[20] 郭素箴, 卢成志. 肌钙蛋白自身抗体与心血管疾病[J]. 国际心血管病杂志, 2013, 40(6): 356-358.
[21] Felix SB, Beug D, Dorr M. Immunoadsorption therapy in dilated cardiomyopathy [J]. Expert Rev Cardiovasc Ther, 2015, 13(2): 145-152.
[22] Wallukat G, Reinke P, Dorffel WV, et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption [J]. Int J Cardiol,1996, 54(2): 191-195.
[23] Herda LR, Felix SB, Staudt A. Immunoadsorption in patients with dilated cardiomyopathy [J]. Atheroscler Suppl, 2009, 10(5): 126-128.
[24] Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution [J]. Circulation, 2001, 103(22): 2681-2686.
[25] Reinthaler M, Empen K, Herda LR, et al. The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms [J]. J Clin Apher, 2015, 30(4):217-223.
[26] Staudt A, Staudt Y, Dorr M, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy [J]. J Am Coll Cardiol, 2004, 44(4): 829-836.
[27] Ameling S, Herda LR, Hammer E, et al. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy [J]. Eur Heart J, 2013, 34(9): 666-675.

备注/Memo

备注/Memo:
基金项目:湖北省生物靶向治疗研究重点实验室基金项目(02.03.2014-10); 中央高校基本科研业务费专项资金资助华中科技大学自主创新研究基金项目(2014QN057) 作者单位:430022 武汉,华中科技大学同济医学院附属协和医院心内科(苏冠华); 430070 武汉,华中科技大学同济医学院附属武汉普爱医院心内科(孙雨霏)
更新日期/Last Update: 2015-12-20